anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation method of bone-setting plaster. The volatile oil is extracted from angelica, notopterygium root and heracleum hemsleyanum michaux after the distilling with water vapor. Mastic, myrrh, red paeony root and semen momordicae are extracted by ethanol. The volatile oil and the residue after the extraction by the ethanol are added with pawpaw, rehmanniae praeparatum and radix asparagi, and then are boiled in the water, the ethanol are filtered and recovered into plaster. Sanguis Draconis is extracted for three times with acetone, and recovered. All extracts are mixed and heated, added with borneol, camphor, mint and plant oil, and then heated until the smelting, and then added with the volatile oil, evenly mixed and rolled into the plaster.
OBJECTIVES: Our study aims to compare the effects of an 8-week high-intensity interval training (HIIT) vs. moderate-intensity continuous training (MICT) on cardiometabolic risk factors and on serum leptin levels in overweight and obese individuals.
METHODS: Our quasi-experimental study involved 36 students who were assigned to HIIT, MICT or the control group. Using a bicycle ergometer, participants in the HIIT group performed 25 min of HIIT and those in the MICT group performed 35 min of moderate-intensity continuous exercise for three days a week for 8 weeks. Body composition estimated by bioimpedance analysis, blood lipids and serum leptin were measured pre-exercise and 8 weeks post-exercise.
RESULTS: After 8 weeks of exercise, the participants in the MICT group showed a significant reduction in weight (p<0.01) and body mass index (BMI) (p<0.05). In the HIIT group, although weight reduction was noticed, the difference was not statistically significant compared to the pre-exercise values. In the control group, participants had a significant increase in their weight, BMI, and total body fat (p<0.05). On performing an inter-group comparison of the magnitude of change in body weight and BMI over 8 weeks of exercise, no difference was seen between the HIIT and MICT groups. No difference was observed in body fat indices and levels of random blood glucose, blood lipids and serum leptin pre and 8 weeks post-exercise.
CONCLUSIONS: On comparing the change in body weight and BMI over 8 weeks, no significant difference was found between the HIIT and MICT groups. However, HIIT was notably more time efficient.
Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
WEGOVY lowers blood glucose and can cause hypoglycemia.

In a trial of adult patients with type 2 diabetes and body mass index (BMI) greater than or equal to 27 kg/m2, hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in 6.2% of WEGOVY-treated patients versus 2.5% of placebo-treated patients. One episode of severe hypoglycemia (requiring the assistance of another person) was reported in one WEGOVY-treated patient versus no placebo-treated patients.

Patients with diabetes mellitus taking WEGOVY in combination with insulin or an insulin secretagogue (e.g., sulfonylurea) may have an increased risk of hypoglycemia, including severe hypoglycemia. Hypoglycemia has been observed in patients treated with semaglutide at doses of 0.5 and 1 mg in combination with insulin. The use of WEGOVY (semaglutide 2.4 mg or 1.7 mg once weekly) in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated. 

Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment. When initiating WEGOVY, consider reducing the dose of concomitantly administered insulin or insulin secretagogue (such as sulfonylureas) to reduce the risk of hypoglycemia [see Drug Interactions (7)].
PURPOSE: A novel antifungal peptide isolated from Solanum tuberosum L cv. Jopung is provided to have an antifungal activity against Candida albicans and to be used in pharmaceutical compositions, cosmetic compositions, agrochemicals, preservatives for foods, cosmetics, and pharmaceutical products. CONSTITUTION: An antifungal peptide has an amino acid sequence of sequence number 1 and is isolated from Solanum tuberosum L cv. Jopung. The molecular weight of the antifungal peptide is 1.0831 kDa. A method for preparing the peptide comprises the steps of: freeze-drying and pulverizing bulbs of Solanum tuberosum L cv. Jopung; extracting the pulverized bulbs and preparing an extract; centrifuging the extract and collecting a supernatant fraction; and isolating and purifying the supernatant fraction by chromatography. An antifungal pharmaceutical composition contains the peptide as an active ingredient.
Stroke causes secondary osteoporosis, falls and fractures. The 2020 Malaysian Stroke Guideline recommends fall and fracture risk assessment in all older stroke patients, but it does not make a firm recommendation on the interventions to address post-stroke bone loss. Stroke increased the risk of fall by 1.5 times compared to the normal population and quadrupled the risk of fracture. Hip fractures will increase the cost for treatment, hospitalization, operation and complicate the rehabilitation process from the stroke itself.

Hence, our study aims to develop and assess the feasibility of a multi-domain intervention (BOUNCE program) for bone health among older adults with acute stroke. A multi-domain non-pharmacological intervention is proposed due to the complex nature of bone loss in older post-stroke patients such as low serum Vitamin D, sarcopenia, frailty, comorbidity, ageing and hemiparesis. Therefore, this study is designed through the 2021 MRC Framework of Developing and Evaluating Complex Intervention and is divided into 3 phases. The first phase is a systematic review to identify evidence on non-pharmacological interventions for post-stroke bone health. Phase 2 is the development and validation of a novel multi-domain intervention protocol for BOUNCE program through an expert consensus development conference. The final phase will be a feasibility trial of BOUNCE program, which is further divided into two components. The first component is a randomized, controlled, single-blinded feasibility trial (RCT) of 6-months intervention (BOUNCE program) versus standard care, which primarily assesses bone loss through bone mineral density and bone turnover markers. The second component is a qualitative analysis through Focused Group Discussions on the feasibility of BOUNCE program among healthcare professionals, patients and carers. The outcome of this study will inform the next step of evaluation, which is a future full RCT to assess the effectiveness and economic studies before it can be implemented widely.
Diet-induced obesity can cause metabolic syndromes. The critical link in disease progression is adipose tissue macrophage (ATM) recruitment, which drives low-level inflammation, triggering adipocyte dysfunction. It is unclear whether ubiquitin-specific proteinase 14 (USP14) affects metabolic disorders by mediating adipose tissue inflammation. In the present study, we showed that USP14 is highly expressed in ATMs of obese human patients and diet-induced obese mice. Mouse USP14 overexpression aggravated obesity-related insulin resistance by increasing the levels of pro-inflammatory ATMs, leading to adipose tissue inflammation, excessive lipid accumulation, and hepatic steatosis. In contrast, USP14 knockdown in adipose tissues alleviated the phenotypes induced by a high-fat diet. Co-culture experiments showed that USP14 deficiency in macrophages led to decreased adipocyte lipid deposition and enhanced insulin sensitivity, suggesting that USP14 plays an important role in ATMs. Mechanistically, USP14 interacted with TNF receptor-associated 6, preventing K48-linked ubiquitination as well as proteasome degradation, leading to increased pro-inflammatory polarization of macrophages. In contrast, the pharmacological inhibition of USP14 significantly ameliorated diet-induced hyperlipidemia and insulin resistance in mice. Our results demonstrated that macrophage USP14 restriction constitutes a key constraint on the pro-inflammatory M1 phenotype, thereby inhibiting obesity-related metabolic diseases.
A method for compiling, storing and organizing data, and gathering and reporting medical intelligence derived from patient-specific data. A patient's Minimum Data Set (“MDS”) data generated by health care facilities are merged with that patient's pharmacy data to create a comprehensive clinical/pharmacological data set for each patient. The data may first be encrypted to ensure patient privacy before being transmitted by the facility to a data repository via an electronic communication network. Upon receipt at the data repository, the data first must pass through a security screen. If the data is determined to be valid and virus-free, it is decrypted as necessary before being added to a data warehouse for use in a wide variety of therapeutic, statistical, and economic analyses. The data may be partially or completely “de-identified” to remove patient-identifying information so as to protect patient privacy.
It is recommended that patients receive premedication with antiemetic agents. In clinical studies of the weekly dosage schedule, the majority of patients received 10 mg of dexamethasone given in conjunction with another type of antiemetic agent, such as a 5-HT3 blocker (e.g., ondansetron or granisetron). Antiemetic agents should be given on the day of treatment, starting at least 30 minutes before administration of CAMPTOSAR. Physicians should also consider providing patients with an antiemetic regimen (e.g., prochlorperazine) for subsequent use as needed. A similar antiemetic regimen should be used with CAMPTOSAR in combination therapy.

Prophylactic or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms.
Medicinal herb poultice is used as a therapeutic, prophylactic and cosmetic means for non-medicamentous effect. Its therapeutic effect is due to the well-selected components in the composition of the therapeutic mixture. It is based on biocomponents of biologically active substances and medicamentous mixtures produced from medicinal herb extract and pulps, the basic carrier being natural resins. The poultice is for multiple use and is in the form of a flat disc of two-side effect. On the one, more active, side the concentration of the biocomponents in the upper layers is higher. On the other side of the disc, along its entire surface, sterile tissue is built in, supporting the structure of the poultice at different temperature changes during its application, ensuring its elasticity, and matching the relief of the treated sector. No chemical products are used in the therapeutic poultice. It is applied on the principle of the phytotherapy, the biologically active vegetative components stimulating the organism by nerve channels and mobilizing its own resistive forces. In proper application the poultice causes no side effects due to the absence of synthetic chemical compositions, preservatives and emulsifiers. 6 claims
Through modulating effects on the gut-brain axis, probiotics are an effective adjuvant treatment for Alzheimer's disease (AD), one of our century's most important medical care challenges (Agahi et al. Front Neurol 9:662, 2018). This trial aimed to examine the effects of two different single-strain probiotics on oxidative stress and inflammation in patients with mild and moderate AD. This was a 12-week placebo-controlled, double-blind, randomized clinical trial performed on 90 patients with AD. Eligible patients were randomly assigned to two different interventions (Lacticaseibacillus rhamnosus HA-114 (7.5 × 109) or Bifidobacterium longum R0175 (7.5 × 109)) and a placebo group, supplemented twice daily. We used mixed-effect models to examine the probiotic's independent effects on clinical results. Significant improvements in serum inflammatory and oxidative stress markers were observed at the end of the trial (P < 0.05). Probiotic supplementation for 12 weeks had beneficial effects on oxidative stress, inflammation, quality of life, and physical activity in patients with mild and moderate AD.
BACKGROUND: Breast cancer is the most common cancer among women and tumour resection carries a high prevalence of chronic persistent postsurgical pain (CPSP). Perioperative i.v. lidocaine infusion has been proposed as protective against CPSP; however, evidence of its benefits is conflicting. This review evaluates the effectiveness of perioperative lidocaine infusions for breast cancer surgery.
METHODS: Randomised trials comparing perioperative lidocaine infusions with parenteral analgesia in breast cancer surgery patients were sought. The two co-primary outcomes were the odds of CPSP at 3 and 6 months after operation. Secondary outcomes included rest pain at 1, 6, 12, and 24 h; analgesic consumption at 0-24 and 25-48 h; quality of recovery; opioid-related side-effects; and lidocaine infusion side-effects. Hartung-Knapp-Sidik-Jonkman (HKSJ) random effects modelling was used.
RESULTS: Thirteen trials (1039 patients; lidocaine: 518, control: 521) were included. Compared with control, perioperative lidocaine infusion did not decrease the odds of developing CPSP at 3 and 6 months. Lidocaine infusion improved postoperative pain at 1 h by a mean difference (95% confidence interval) of -0.65 cm (-0.73 to -0.57 cm) (P<0.0001); however, this difference was not clinically important (1.1 cm threshold). Similarly, lidocaine infusion reduced oral morphine consumption by 7.06 mg (-13.19 to -0.93) (P=0.029) over the first 24 h only; however, this difference was not clinically important (30 mg threshold). The groups were not different for any of the remaining outcomes.
CONCLUSIONS: Our results provide moderate-quality evidence that perioperative lidocaine infusion does not reduce CPSP in patients undergoing breast cancer surgery. Routine use of lidocaine infusions for perioperative analgesia and CPSP prevention is not supported in this population.
SYSTEMATIC REVIEW PROTOCOL: PROSPERO CRD42023420888.
NEW MATERIAL:The compound of formula (R is H of Tyr-Gly; Thr may be labeled with radioactive iodine). USE:Determination of interferon-gamma free from sugar chain and prepared by a genetic engineering method. PREPARATION:For example, a copolymer of chloromethylated styrene and divinylbenzene is made to react with the cesium salt of a C-terminated amino acid having t-butoxycarbonylated amino group to effect the bonding of the salt to a solid carrier, and the amino-protecting group is removed. The product is made to react with an amino-protected amino acid according to the amino acid sequence of the peptide in the presence of a condensation agent, and the amino-protecting group is removed. The above operation is repeated to synthesize the objective peptide. The compound of formula can be obtained by removing all the protecting groups from the peptide and separating the peptide from the solid carrier.
INTRODUCTION: Postoperative sepsis represents a rare complication following thyroidectomy. We aimed to explore the incidence, risk factors, sources, and outcomes of postoperative sepsis and septic shock among adult patients undergoing thyroidectomy.
METHODS: Data from the American College of Surgeons National Surgical Quality Improvement Program were used in this retrospective cohort study. Patients aged ≥18 y who underwent elective thyroidectomy between 2005 and 2019 were included. Multivariable binary logistic regression models were computed to explore risk factors and outcomes of 30-d sepsis and septic shock.
RESULTS: Among the 180,373 included patients, 0.1% developed sepsis or septic shock. Male gender, low body mass index, American Society of Anesthesiologists classes 3-5, functional dependence, smoking, diabetes mellitus, pulmonary disease, inpatient surgery, malignant indication, clean-contaminated wound classification, and operation time ≥150 min were significant risk factors for development of sepsis or septic shock. Common infectious sources of sepsis included surgical site infections (29.6%), pneumonia (18.6%), urinary tract infections (16.2%), and multiple infections (6.9%). Patients with postoperative sepsis or septic shock were significantly more likely to develop complications, including wound disruption, stroke, cardiac and renal complications, thromboembolism, prolonged length of stay, unplanned reoperation, and mortality.
CONCLUSIONS: Sepsis is rare following thyroidectomy. Our study provides insight into risk factors and procedural characteristics which may contribute to the development of postoperative sepsis or septic shock in this population.
This is a prospective, single-center, open-label, randomized within-subject-controlled trial. We aim to randomize 100 patients undergoing isolated coronary artery bypass graft (CABG). We consecutively screen patients during the study enrollment period and seek informed consent from all eligible patients. In each patient, one saphenous vein graft (SVG) will be randomized to be the proximal segment, while another will be the distal segment as control. Healing of leg wounds will be assessed on day 6 post-operatively. Follow-up will be performed via face-to-face interview until at least 1 year after the operation by CT angiography.
PURPOSE:To obtain the title composition improved in the luscious taste unique to the original composition, with plain taste, good in use feeling by formulating a specified amount of l-menthyl acetate in a composition for use in the oral cavity containing tranexamic acid and triclosan. CONSTITUTION:The objective composition can be obtained by formulating (A) a composition for use in oral cavity effective for preventing periodontosis containing each pref. 0.001-1 (esp. 0.01-0.5)wt.% of (1) tranexamic acid having both high anti-inflammatory and anti-hemorrhagic effects and (2) triclosan capable of inhibiting production of bacterial plaque on teeth by its powerful bactericidal activity with (B) 0.002-0.5 (pref. 0.005-0.1)wt.% of l-menthyl acetate. The present composition is free from the luscious taste inherent in both tranexamic acid and triclosan, being plain in taste and very favorable in use feeling.
A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small "sticker" electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds.
The invention relates to a preparing method of a stable type stonecrop herb extracted and purified matter, belonging to the technical field of medicine. The stable type stonecrop herb extracted and purified matter of the invention is obtained by the steps of taking the dry stringy stonecrop herb medicine as the raw material, extracting with ethanol, concentrating and extracting in continuous backflow by benzine, dissolving the paste medicine which evaporates to dry in water to become solution, absorbing with big-pore resin column, eluting with water primarily and then with 75 percent of the ethanol and concentrating and drying. The preparing method of the stable type stonecrop herb extracted and purified matter of the invention, through formal test and design, the extracting technique is the most preferable and the effective components such as flavone, etc., in the stringy stonecrop herb is improved as much as possible. The technological flow is simple and the period is short to be free from seasonal limits. The obtained stonecrop herb extracted and purified matter has stable quality. The adopted reagent has no residue of harmful matter, and the cost is low, thus, the invention is applicable for industrialized production in large scale.
Patients will be treated with tasquinimod capsules 0.5 mg/day for 14 days (half cycle) and then capsules of 1 mg/day for the remaining 14 days in the first cycle. In consecutive 28-day cycles 1 mg/day (or if 1 mg/day is not tolerated, reduction to 0.75 or 0.5 mg/day is allowed, followed by dose re-escalation whenever possible). Patients will be treated for a maximum period of 24 weeks (6 cycles).
<P>PROBLEM TO BE SOLVED: To obtain a composition for suppressing rise in blood sugar level, in its turn, a food and beverage or a medicine containing the composition.  <P>SOLUTION: The composition for suppressing rise in blood sugar level comprises a component of Acer buergerianum Miq. or Acer carpinifolium Sieb. et Zucc. The food and beverage or the medicine contains the composition.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The present invention relates to compositions and kits for influencing, in a targeted manner, energy metabolism in muscular and fatty tissue. In detail, the invention teaches a composition or a kit which provides the three components insulin, IGF-1 and IGFBP-2. The three components can be present in the composition or the kit as protein or can be encoded by at least one nucleic acid contained in the composition or the kit, the nucleic acid preferably being RNA. The invention further discloses the use of the composition or the kit in a method for increasing the intramuscular fat content in the meat of farm animals or in culture in vitro. The composition or kit according to the invention can also be a pharmaceutical composition or a pharmaceutical kit, which can be used in treating insulin resistance, muscular dystrophy, in preserving and regenerating neural functions and in treating and/or preventing neuropathy. Finally, the present invention discloses the use of the pharmaceutical composition and the pharmaceutical kit according to the invention in treating injuries to muscles, ligaments and/or tendons in a subject.
Participants will undergo Fluciclovine PET/CT within 30 days of a negative or equivocal PSMA PET scan. After the Fluciclovine PET/CT, the patient will follow up with their treating physician as per standard-of-care. The research team will collect clinical and imaging data at 6 months post Fluciclovine-PET/CT.
Luobuma tea is made from the leaves of Apocynum hendersonii (Bt) and A. venetum (Ht) and has been used for a very long time in China and Japan as herbal tea. This study isolated water-soluble polysaccharides from the two species` teas. Physicochemical properties, structural properties, in vitro and in vivo antioxidant and immunomodulatory activities were determined for the first time. The results showed that the Bt and Ht polysaccharides with molecular weights of 31.21 and 49.11 kDa, respectively, composed of arabinose, galactose, rhamnose, glucose, xylose, fucose, and mannose. A dose-dependent nitric oxide production and interleukin-6 inhibitory effects were obtained. Also, they suppressed the expression of cyclooxygenase-2, tumor necrosis factor-α and interleukin-6 mRNA in LPS-induced RAW 264.7 macrophages. Likewise, Bt and Ht have significantly reduced edema in the paws of mice after carrageenan injection. These results suggested that the Luobuma teas polysaccharides can be explored as potential antioxidants and anti-inflammatory agents.
PURPOSE: A pharmaceutical composition containing protuboxepin A, B and protubonnine A is provided to suppress cancer cell proliferation and to prevent or treat cancer. CONSTITUTION: A novel protuboxepin A, B and protubonnine A is denoted by chemical formulas 1-3. A pharmaceutical composition for preventing or treating cancer contains the compounds as an active ingredient. The cancer includes breast cancer, liver cancer, or myelocytic leukemia. A health food for preventing or treating cancer contains the compounds as an active ingredient. A method for preparing the compounds comprises: a step of culturing Aspergillus sp. SF-5044; a step of extracting the strain culture with ethyl acetate; and a step of isolating the extract through column chromatography.